Delivering Anti-Infectives

AiCuris is an international clinical-stage biopharmaceutical company, dedicated to the development of novel, therapeutic candidates for the prevention and treatment of severe and potentially life-threatening infectious diseases in immunocompromised patients.
The Company is focused on advancing its highly differentiated product portfolio, leveraging its research and clinical development expertise to bring game-changing, high growth potential product candidates to the market and thereby to vulnerable patients with a high need for anti-infectives treatment options.

• Demonstrated ability in delivering novel treatment options:
  PREVYMIS® (letermovir), the Company’s first-in-class antiviral agent for prophylactic use in allogeneic hematopoietic stem cell (HSC) and kidney transplant patients, prevents life-threatening cytomegalovirus (CMV) reactivation, is marketed by MSD (tradename of Merck & Co., Inc.) and generates increasing revenues.
• Candidate with fast track to market:
  Pritelivir, a proprietary product candidate for the treatment of acyclovir resistant herpes simplex virus (HSV) infections in immunocompromised patients is currently in phase 3 development and obtained FDA breakthrough designation. Launch preparations have been initiated at AiCuris.
• Innovative pipeline of anti-infectives:
  The anti-sense oligonucleotide (ASO) AIC468 aims to prevent active infection of BK virus (BKV) in kidney transplanted patients and is expected to enter clinical testing early next year. Preclinical programs targeting Adenovirus infections are positioned to aim to treat transplant patients, as well as ocular infections in the general population.

With a solid financial position and highly experienced management team, AiCuris is on its way to becoming a fully integrated biopharmaceutical company covering the entire value chain from research through clinical development to commercialization.